samedan logo
 
 
 
spacer
home > pmps > summer 2020 > cracking the code mark in pharma labelling
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Cracking the Code Mark in Pharma Labelling

Pharmaceutical labelling has always been a key part of a product’s integrity. The label carries vital information on the drug type and strength, as well as traceability information printed onto the label at the point of packaging.

Unlike a food product, where the consumer can detect possible toxicity through colour, smell, or taste, there is no such ‘point of use’ check with a pharmaceutical product. The user trusts that product has been correctly formulated and packed with no risk of contamination, following GMP guidelines.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Richard Pether is a director at Rotech Machines. He holds a degree in Mechanical Engineering and has spent over 30 years working with pharma producers in the UK and around the world. While his speciality is in the field of all variations of coding and marking, he is also keenly interested in vision and verification systems that are increasingly found alongside coding systems. Richard has also been instrumental in the development of feeding systems for offline coding of pharmaceutical products.
spacer
Richard Pether at Rotech Machines
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Europital forecast 30% CAGR from UK biotech for three years

Europital – the global provider of medical management services for clinical research and drug development – announces it is opening a UK site to further expand its services to the UK biotech industry.
More info >>

White Papers

Clinical Trials in Russia Orange Paper: Summary of Year 2013

Synergy Research Group

Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement